8-K: MAIA Biotech Advances Lung Cancer Drug Ateganosine

MAIA Biotechnology highlights ongoing momentum for its ateganosine clinical program for non-small cell lung cancer, including patient enrollment and promising survival data.

Summary

• MAIA Biotechnology presented two "Trials in Progress" posters at SITC 2025, focusing on its Phase 2 THIO-101 expansion (Part C) and Phase 3 THIO-104 clinical trials for ateganosine in non-small cell lung cancer (NSCLC).
• Ateganosine, a first-in-class small molecule telomere targeting agent, has received Fast Track designation from the U.S. FDA for NSCLC treatment.
• The Phase 2 THIO-101 expansion trial has enrolled 12 patients to date, with enrollment now underway in European Medicines Agency (EMA) countries including Hungary, Poland, Turkey, and Taiwan.
• Patient screening has commenced for the Phase 3 THIO-104 trial.
• One patient in the THIO-101 Phase 2 trial, who began therapy in March 2023, has shown survival of 30 months (912 days) as of September 17, 2025.
• The overall survival (OS) observed in THIO-101 to date is 17.8 months, significantly higher than the approximately 6 months OS for current third-line NSCLC treatments resistant to chemo and immunotherapy.

Sentiment

Score: 8

Explanation: The filing reports significant positive clinical trial momentum, including patient enrollment expansion, initiation of a Phase 3 trial, FDA Fast Track designation, and highly encouraging survival data (17.8 months OS vs. 6 months standard) for a difficult-to-treat cancer population. This indicates strong progress and potential for the lead drug candidate.

Positives

• Ongoing momentum in the ateganosine clinical program, highlighted at a major industry conference (SITC 2025).
• FDA Fast Track designation for ateganosine in NSCLC, potentially accelerating regulatory review.
• Phase 2 THIO-101 expansion trial has enrolled 12 patients and expanded into EMA countries, indicating progress and broader reach.
• Commencement of patient screening for the Phase 3 THIO-104 trial, marking a significant advancement in the development pipeline.
• Promising survival data from the Phase 2 THIO-101 trial, with one patient achieving 30 months (912 days) survival.
• Observed overall survival (OS) of 17.8 months in THIO-101 to date, which is substantially better than the approximately 6 months OS for current standard treatments in third-line NSCLC patients.
• Ateganosine's novel mechanism of action, activating both innate and adaptive immune responses, suggests a differentiated therapeutic approach.

Risks

• The initiation, timing, cost, progress, and results of preclinical and clinical studies and research and development programs.
• Ability to advance product candidates into, and successfully complete, clinical studies.
• Timing or likelihood of regulatory filings and approvals.
• Ability to develop, manufacture, and commercialize product candidates and improve the manufacturing process.
• Rate and degree of market acceptance of product candidates.
• Size and growth potential of the markets for product candidates and ability to serve those markets.
• Ability to obtain and maintain intellectual property protection for product candidates.

Future Outlook

The company anticipates further momentum in identifying and enrolling patients for THIO-101 Part C in the near term. Management believes that the promising 17.8 months overall survival observed in THIO-101, compared to 6 months for current treatments, could lead to an early commercial approval of ateganosine by the FDA for third-line NSCLC patients resistant to chemo and immunotherapy. The CEO states that bringing the novel NSCLC treatment to this large patient population with significant unmet medical need is "only a matter of successful execution."

Management Comments

• "It was a privilege to return to SITC for its 40th anniversary. This event was an ideal forum to highlight the continued success of our Phase 2 clinical trial. We are making steady progress in the expansion phase of this trial, with patient enrollment now underway in European Medicines Agency (EMA) countries. Sites in Hungary and Poland, which were instrumental in Parts A and B of the trial, are actively screening patients along Turkey and Taiwan, and we have 12 patients enrolled in the expansion to date. We expect further momentum in identifying and enrolling patients for THIO-101 Part C in the near term." Victor Zaporojan, M.D., Sr. Medical Director.
• "We also began screening patients in our Phase 3 trial, THIO-104, and noticed great excitement from physicians in the sites were bringing our trial to. In this population, third-line NSCLC patients resistant to chemo and immunotherapy, current treatments show overall survival (OS) of around 6 months, and based on the 17.8 months OS observed in THIO-101 to date, we believe that our Phase 3 trial could lead to an early commercial approval of ateganosine by the FDA. Its only a matter of successful execution to bring our novel NSCLC treatment to this large patient population with significant unmet medical need." Vlad Vitoc, M.D., CEO.
• "A novel therapy with proven efficacy, such as ateganosine, could strengthen existing treatment strategies and further advance the principles of precision oncology in lung cancer care worldwide. In Poland, where improving outcomes in advanced NSCLC remains a central focus, ateganosine has the potential to become an important addition to the therapeutic landscape, offering new hope for patients and clinicians alike." Tomasz Jankowski, M.D., Ph.D., key investigator for THIO-101 in Poland.

Industry Context

The announcement positions ateganosine as a potential significant advancement in the treatment of advanced non-small cell lung cancer (NSCLC), particularly for third-line patients who have developed resistance to existing checkpoint inhibitors and chemotherapy. This patient population currently faces limited options and poor prognosis (around 6 months OS). Ateganosine's novel telomere-targeting mechanism and its ability to activate both innate and adaptive immune responses could offer a new therapeutic strategy, potentially strengthening existing treatment paradigms and advancing precision oncology. The FDA Fast Track designation underscores the recognized unmet medical need and the potential of ateganosine.

Comparison to Industry Standards

• Current treatments for third-line NSCLC patients resistant to chemo and immunotherapy show an overall survival (OS) of approximately 6 months.
• Ateganosine, in the THIO-101 trial, has shown an observed overall survival (OS) of 17.8 months to date, which is significantly higher than the industry standard for this patient population.
• One patient in the THIO-101 Phase 2 trial achieved 30 months (912 days) survival, demonstrating exceptional individual response compared to the typical prognosis.

Stakeholder Impact

• Shareholders: Positive impact due to significant clinical progress, promising survival data, and FDA Fast Track designation, which could lead to accelerated approval and increased market value.
• Patients: Potential for a novel and significantly more effective treatment option for advanced NSCLC patients who have exhausted current therapies, offering extended survival and improved quality of life.
• Medical Community: Ateganosine could become an important addition to the therapeutic landscape for NSCLC, strengthening existing treatment strategies and advancing precision oncology.

Next Steps

• Further momentum in identifying and enrolling patients for THIO-101 Part C in the near term.
• Successful execution of the Phase 3 THIO-104 trial to potentially lead to early commercial approval by the FDA.

Key Dates

Recommendation

The filing presents compelling evidence of ateganosine's potential, particularly the 17.8 months overall survival observed in a challenging patient population where current treatments yield only 6 months. The FDA Fast Track designation, combined with the initiation of a Phase 3 trial and expanding patient enrollment, significantly de-risks the development pathway and points towards a high probability of regulatory success and market adoption. This strong clinical data and regulatory support suggest a substantial upside for the company's stock.

Keywords

MAIA Biotechnology, Ateganosine, THIO, NSCLC, Non-Small Cell Lung Cancer, Immunotherapy, Cancer Treatment, Clinical Trials, Phase 2, Phase 3, FDA Fast Track, Telomere Targeting, Oncology, Biopharmaceutical, SITC 2025